vs
Side-by-side financial comparison of National Storage Affiliates Trust (NSA) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
National Storage Affiliates Trust is the larger business by last-quarter revenue ($187.0M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -1.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -2.4%).
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
NSA vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $187.0M | $129.7M |
| Net Profit | $22.9M | — |
| Gross Margin | 72.5% | 98.0% |
| Operating Margin | 20.2% | -25.0% |
| Net Margin | 12.2% | — |
| Revenue YoY | -1.6% | 73.4% |
| Net Profit YoY | 36.8% | — |
| EPS (diluted) | $0.23 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $187.0M | $129.7M | ||
| Q3 25 | $188.7M | $164.9M | ||
| Q2 25 | $188.8M | $114.4M | ||
| Q1 25 | $188.4M | $81.7M | ||
| Q4 24 | $190.1M | $74.8M | ||
| Q3 24 | $193.6M | $62.9M | ||
| Q2 24 | $190.4M | $54.1M | ||
| Q1 24 | $196.1M | $41.4M |
| Q4 25 | $22.9M | — | ||
| Q3 25 | $18.4M | $25.7M | ||
| Q2 25 | $19.5M | $-12.8M | ||
| Q1 25 | $13.0M | $-41.2M | ||
| Q4 24 | $16.7M | — | ||
| Q3 24 | $18.7M | $-54.8M | ||
| Q2 24 | $17.1M | $-70.4M | ||
| Q1 24 | $59.0M | $-136.1M |
| Q4 25 | 72.5% | 98.0% | ||
| Q3 25 | 70.7% | 99.0% | ||
| Q2 25 | 70.5% | 98.7% | ||
| Q1 25 | 70.7% | 94.3% | ||
| Q4 24 | 72.5% | 96.6% | ||
| Q3 24 | 72.8% | 97.4% | ||
| Q2 24 | 72.6% | 96.2% | ||
| Q1 24 | 72.1% | 96.4% |
| Q4 25 | 20.2% | -25.0% | ||
| Q3 25 | 15.8% | 15.1% | ||
| Q2 25 | 16.5% | -11.1% | ||
| Q1 25 | 11.0% | -52.2% | ||
| Q4 24 | 14.5% | -81.2% | ||
| Q3 24 | 15.8% | -89.3% | ||
| Q2 24 | 17.2% | -125.1% | ||
| Q1 24 | 48.9% | -336.5% |
| Q4 25 | 12.2% | — | ||
| Q3 25 | 9.8% | 15.6% | ||
| Q2 25 | 10.3% | -11.1% | ||
| Q1 25 | 6.9% | -50.4% | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 9.7% | -87.1% | ||
| Q2 24 | 9.0% | -130.1% | ||
| Q1 24 | 30.1% | -328.9% |
| Q4 25 | $0.23 | $0.04 | ||
| Q3 25 | $0.17 | $0.28 | ||
| Q2 25 | $0.19 | $-0.14 | ||
| Q1 25 | $0.10 | $-0.47 | ||
| Q4 24 | $0.19 | $-0.71 | ||
| Q3 24 | $0.18 | $-0.70 | ||
| Q2 24 | $0.16 | $-0.91 | ||
| Q1 24 | $0.65 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $946.0M | $114.8M |
| Total Assets | $5.1B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.3M | $93.0M | ||
| Q3 25 | $26.3M | $110.9M | ||
| Q2 25 | $26.1M | $75.2M | ||
| Q1 25 | $19.3M | $61.9M | ||
| Q4 24 | $50.4M | $58.5M | ||
| Q3 24 | $69.9M | $36.4M | ||
| Q2 24 | $59.0M | $32.3M | ||
| Q1 24 | $64.2M | $43.3M |
| Q4 25 | $946.0M | $114.8M | ||
| Q3 25 | $973.1M | $73.6M | ||
| Q2 25 | $1.0B | $32.7M | ||
| Q1 25 | $1.0B | $32.8M | ||
| Q4 24 | $1.1B | $59.1M | ||
| Q3 24 | $986.9M | $-30.5M | ||
| Q2 24 | $1.2B | $15.1M | ||
| Q1 24 | $1.3B | $74.1M |
| Q4 25 | $5.1B | $605.2M | ||
| Q3 25 | $5.1B | $538.6M | ||
| Q2 25 | $5.2B | $555.3M | ||
| Q1 25 | $5.3B | $548.8M | ||
| Q4 24 | $5.4B | $594.1M | ||
| Q3 24 | $5.4B | $504.4M | ||
| Q2 24 | $5.3B | $551.1M | ||
| Q1 24 | $5.4B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $338.5M | $60.7M |
| Free Cash FlowOCF − Capex | $299.8M | — |
| FCF MarginFCF / Revenue | 160.3% | — |
| Capex IntensityCapex / Revenue | 20.7% | — |
| Cash ConversionOCF / Net Profit | 14.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $541.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $338.5M | $60.7M | ||
| Q3 25 | $100.2M | $14.3M | ||
| Q2 25 | $79.9M | $5.0M | ||
| Q1 25 | $85.6M | $-42.2M | ||
| Q4 24 | $363.1M | $-35.7M | ||
| Q3 24 | $105.7M | $-42.5M | ||
| Q2 24 | $83.2M | $-40.2M | ||
| Q1 24 | $94.0M | $-119.0M |
| Q4 25 | $299.8M | — | ||
| Q3 25 | $88.0M | $14.2M | ||
| Q2 25 | $73.8M | — | ||
| Q1 25 | $79.9M | — | ||
| Q4 24 | $344.4M | — | ||
| Q3 24 | $101.8M | — | ||
| Q2 24 | $79.5M | $-40.3M | ||
| Q1 24 | $88.6M | — |
| Q4 25 | 160.3% | — | ||
| Q3 25 | 46.6% | 8.6% | ||
| Q2 25 | 39.1% | — | ||
| Q1 25 | 42.4% | — | ||
| Q4 24 | 181.2% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 41.7% | -74.5% | ||
| Q1 24 | 45.2% | — |
| Q4 25 | 20.7% | — | ||
| Q3 25 | 6.5% | 0.1% | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 1.9% | 0.2% | ||
| Q1 24 | 2.7% | 0.0% |
| Q4 25 | 14.79× | — | ||
| Q3 25 | 5.44× | 0.56× | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 6.59× | — | ||
| Q4 24 | 21.70× | — | ||
| Q3 24 | 5.65× | — | ||
| Q2 24 | 4.88× | — | ||
| Q1 24 | 1.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSA
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
